The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation

To the editor: In 1998 a female patient received an allogeneic stem cell (SC) transplant from her sister 9 months after she was diagnosed with a high risk myelodysplastic syndrome (RAEB2) and was treated with chemotherapy aiming to achieve complete remission. A myeloablative conditioning regime was